Fermbox Bio, a synthetic biology company, focused on using microbial precision fermentation, for sustainable and commercially viable production, of bio-alternatives to those derived from plants and animals, has announced its collaboration agreement with Dyadic International Inc. This collaboration will bring together Fermbox’s extensive product development and scale up process engineering capabilities and Dyadic’s proprietary Dapibus™ filamentous fungal based microbial protein production platform and to design, develop and commercialize innovative animal free alternative proteins and biomaterials.

“We are very excited to partner with Dyadic and use its novel Dapibus™ platform to create alternative biomaterials that are not only sustainable but also economically viable. Our joint expertise across expression systems and execution capabilities from lab to large scale manufacturing, uniquely positions us for success. We have a long-standing relationship with Dyadic leadership, and we believe that this co-development agreement can potentially accelerate the timelines for both companies to bring new and commercially viable bio-alternates to the market sooner,” commented Mr. Subramani (suBBu) Ramachandrappa, Founder of Fermbox Bio.

“Having operations both in the US and in India, Fermbox is uniquely positioned to collaborate globally and use its advantage of access to Indian scientific talent and manufacturing capabilities locally. We are of the opinion that the synthetic biology industry will follow our model to increase success rates for product development and viable commercialization. We are pleased to embark on this journey with Dyadic and are keen to put our collaboration to work, bringing our complementary skills to action.”

“I am excited to announce this fully funded co-development and marketing agreement with Fermbox which is consistent with our business strategy of focusing on near term commercialization opportunities that can create shareholder value,” said Joe Hazelton, Chief Business Officer of Dyadic.

“Fermbox has extensive expertise in bio-alternate development and microbial precision fermentation which we expect will accelerate our ability to exploit the Dapibus™ platform and expand Dyadic’s product offerings for non-pharmaceutical alternative proteins applications, such as food, nutrition, wellness and other bioproducts.

We anticipate this collaboration will enhance our market penetration into the alternative protein markets at the same time our biopharmaceutical activities using C1 are also advancing at a rapid pace. We believe that this collaboration will further leverage our proprietary Dapibus™ platform toward developing and commercializing multiple end-market animal free protein products.”

Visit the Fermbox website or use the green "Request Information" button to contact Fermbox for more details.